Table 1. Patient demographic and clinical data.
| No AKI | AKIN1 | AKIN2 | AKIN3 | |
|---|---|---|---|---|
| Number | 16 | 24 | 13 | 12 |
| Males | 10 (63%) | 21(88%) | 11(85%) | 9(75%) |
| Median age (years) (range) | 30 (15–50) | 41 (16–66) | 51 (18–71) | 49.5 (22–76) |
| Median weight (kg) (range) | 54 (40–66) | 55 (46–68) | 65 (45–70) | 56.5 (40–70) |
| Median time to admission | 1h 27min | 1h 30min | 1h 10min | 1h 50min |
| Site of bite | ||||
| Lower Limb | 14 | 22 | 12 | 12 |
| Upper Limb | 2 | 1 | - | - |
| Clinical manifestations | ||||
| Local signs and symptoms (pain and/or swelling) |
14 (88%) | 18 (75%) | 12 (92%) | 12 (100%) |
| Positive WBCT20 | 8 (53%) | 19 (86%0 | 8 (67%) | 12 (100%) |
| Bleeding (Haematemesis/ haematuria/ bleeding from bite site/ IV site) |
2 (13%) | 5 (21%) | 6 (46%) | 4 (33%) |
| Neurotoxicity | 9 (56%) | 10 (42%) | 9 (69%) | 8 (67%) |
| Median venom concentration (ng/ml) (range) | 59 (2–1456) (n = 10) | 50 (2–972) (n = 16) | 351 (2–3125) (n = 13) | 483 (2–2244) (n = 10) |
| Treatment with antivenom | 15 (94%) | 22 (92%) | 12 (92%) | 12 (100%) |
Neurotoxicity was the presence of any of ptosis, diplopia, blurred vision